Engineered nanomicelles inhibit the tumour progression via abrogating the prostaglandin-mediated immunosuppression
Poonam Yadav,Kajal Rana,Viviani Nardini,Ali Khan,Trishna Pani,Animesh Kar,Dolly Jain,Ruchira Chakraborty,Ragini Singh,Somesh K Jha,Devashish Mehta,Harsh Sharma,Ravi Datta Sharma,S V S Deo,Sagar Sengupta,Veena S Patil,Lúcia Helena Faccioli,Ujjaini Dasgupta,Avinash Bajaj,Somesh K. Jha,S.V.S. Deo,Veena S. Patil
DOI: https://doi.org/10.1016/j.jconrel.2024.03.009
IF: 11.467
2024-03-15
Journal of Controlled Release
Abstract:Cancer treatment is challenged due to immunosuppressive inflammatory tumour microenvironment (TME) caused by infiltration of tumour-promoting and inhibition of tumour-inhibiting immune cells. Here, we report the engineering of chimeric nanomicelles (NMs) targeting the cell proliferation using docetaxel (DTX) and inflammation using dexamethasone (DEX) that alters the immunosuppressive TME. We show that a combination of phospholipid-DTX conjugate and PEGylated-lipid-DEX conjugate can self-assemble to form sub-100 nm chimeric NMs (DTX-DEX NMs). Anti-cancer activities against syngeneic and xenograft mouse models showed that the DTX-DEX NMs are more effective in tumour regression, enhance the survival of mice over other treatment modes, and alter the tumour stroma. DTX-DEX NMs cause a significant reduction in myeloid-derived suppressor cells, alter the polarization of macrophages, and enhance the accumulation of cytotoxic CD4 + and CD8 + T cells in tumour tissues, along with alterations in cytokine expression. We further demonstrated that these DTX-DEX NMs inhibit the synthesis of prostaglandins, especially PGE2, by targeting the cyclooxygenase 2 that is partly responsible for immunosuppressive TME. Therefore, this study presents, for the first time, the engineering of lithocholic acid-derived chimeric NMs that affect the prostaglandin pathway, alter the TME, and mitigate tumour progression with enhanced mice survival.
pharmacology & pharmacy,chemistry, multidisciplinary